(Q51485541)

5 April 2018

title

Thiazolidinediones improve beta-cell function in type 2 diabetic patients. (English)

1 reference

5 April 2018

1 reference

1

1 reference

5 April 2018

Masafumi Matsuda

4

1 reference

5 April 2018

Ralph A. DeFronzo

6

object named as

Ralph A DeFronzo

1 reference

5 April 2018

2

Ele Ferrannini

1 reference

5 April 2018

author name string

Yoshinori Miyazaki

3

1 reference

5 April 2018

Andrea Mari

5

1 reference

5 April 2018

publication date

14 November 2006

1 reference

5 April 2018

American Journal of Physiology - Endocrinology and Metabolism

published in

1 reference

5 April 2018

volume

292

1 reference

5 April 2018

issue

3

1 reference

5 April 2018

page(s)

E871-83

1 reference

5 April 2018

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Measurement of size and turnover rate of body glucose pool by the isotope dilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Glucose clamp technique: a method for quantifying insulin secretion and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The effect of pioglitazone on the liver: role of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Muscle-specific Pparg deletion causes insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Glimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00551.2006

10.1152/AJPENDO.00551.2006

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

17106061

1 reference

5 April 2018